Eusébio Marta, Caldeira Paulo, Antunes Artur Gião, Ramos André, Velasco Francisco, Cadillá Jesús, Guerreiro Horácio
Gastroenterology Departament, Centro Hospitalar do Algarve, EPE, Faro, Portugal.
Pathology Department, Centro Hospitalar do Algarve, EPE, Faro, Portugal.
GE Port J Gastroenterol. 2015 Oct 20;23(2):91-95. doi: 10.1016/j.jpge.2015.09.005. eCollection 2016 Mar-Apr.
We report a case of a 63-year-old-man presenting with chronic diarrhea and weight loss while on olmesartan treatment for hypertension. Investigation showed multiple nutritional deficiencies associated with diffuse intestinal villous atrophy. Serologies for celiac disease were negative and other causes of villous atrophy were excluded. Olmesartan as a precipitant agent was suspected and withdrawn. Clinical improvement occurred in days with no need for other therapeutic measures. Follow-up at three months showed clinical remission and almost complete recovery of intestinal atrophy. Olmesartan is an angiotensin receptor blocker commonly prescribed for the management of hypertension. Spruelike enteropathy associated with this drug is a recently described entity with few cases reported. It presents with chronic diarrhea and intestinal villous atrophy and should be included in its differential diagnosis. This case intends to alert clinicians for the possibility of this event in a patient on treatment with this drug.
我们报告了一例63岁男性病例,该患者在接受奥美沙坦治疗高血压期间出现慢性腹泻和体重减轻。检查显示存在多种营养缺乏,并伴有弥漫性肠绒毛萎缩。乳糜泻血清学检查为阴性,其他导致绒毛萎缩的原因也被排除。怀疑奥美沙坦为诱发因素并停用。数天内临床症状改善,无需其他治疗措施。三个月后的随访显示临床缓解,肠萎缩几乎完全恢复。奥美沙坦是一种常用于治疗高血压的血管紧张素受体阻滞剂。与这种药物相关的类麦胶性肠病是一种最近才被描述的疾病,报告的病例很少。它表现为慢性腹泻和肠绒毛萎缩,在鉴别诊断中应予以考虑。本病例旨在提醒临床医生,使用该药物治疗的患者可能会发生这种情况。